These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4711847)

  • 1. Hyperkalemic cardiac arrhythmia secondary to spironolactone.
    Pongpaew C; Songkhla RN; Kozam RL
    Chest; 1973 Jun; 63(6):1023-5. PubMed ID: 4711847
    [No Abstract]   [Full Text] [Related]  

  • 2. [A successfully treated case of spironolactone-induced hyperkalemic quadriplegia].
    Radó J; Csabuda M
    Orv Hetil; 1985 Aug; 126(32):1967-70, 1973-4. PubMed ID: 2993981
    [No Abstract]   [Full Text] [Related]  

  • 3. Iatrogenic hyperkalemic paralysis with electrocardiographic changes.
    Kalbian VV
    South Med J; 1974 Mar; 67(3):342-5. PubMed ID: 4814187
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia.
    Yap V; Patel A; Thomsen J
    JAMA; 1976 Dec; 236(24):2775-6. PubMed ID: 1036572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
    Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
    Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Spironolactone and potassium].
    Kjeldsen K
    Ugeskr Laeger; 2004 Nov; 166(48):4392; author reply 4392-3. PubMed ID: 15587639
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elderly heart failure patients with drug-induced serious hyperkalemia.
    Vanpee D; Swine CH
    Aging (Milano); 2000 Aug; 12(4):315-9. PubMed ID: 11073352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone in patients with heart failure.
    Vanpee D; Swine C
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
    Radó JP; Marosi J; Takó J; Dévényi I
    Am Heart J; 1968 Sep; 76(3):393-8. PubMed ID: 4951338
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure].
    Bednarz B; Cybulski J; Chamiec T
    Pol Merkur Lekarski; 2000 Aug; 9(50):519-21. PubMed ID: 11081314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone in patients with heart failure.
    Larkin RJ; Atlas SA; Donohue TJ
    N Engl J Med; 2000 Jan; 342(2):132-3; author reply 133-4. PubMed ID: 10636751
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone therapy in heart failure patients with chronic kidney disease.
    Lopes R; Lourenco P; Mascarenhas J; Azevedo A; Bettencourt P
    Clin Cardiol; 2009 Oct; 32(10):597. PubMed ID: 19911355
    [No Abstract]   [Full Text] [Related]  

  • 20. High potassium. Too much of a good thing.
    Mayo Clin Health Lett; 2009 Feb; 27(2):6. PubMed ID: 19360981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.